Results 11 to 20 of about 23,087 (229)
Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours [PDF]
Health Technology Assessment, 2013 Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford +10 more
doaj +2 more sources
Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis [PDF]
Drug, Healthcare and Patient Safety, 2011 E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the ...
Lewiecki EM
doaj +2 more sources
Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia? [PDF]
, 2021 The prevalence of sarcopenia with osteoporosis results in a higher risk of falling and fractures. It was noted that patients who had completed their planned 5-year denosumab therapy course as treatment for these conditions started to sustain falls.
Hegazi, Mohamed Osama +10 more
core +1 more source
ESMO Open, 2020 Objectives Giant cell tumour of bone (GCTB) is a rare tumour, generally managed with surgery. Treatment of the very rare unresectable advanced/metastatic GCTB is challenging and denosumab is the only current available medical option, an anti-RANKL ...
Alessandra Raimondi +9 more
doaj +1 more source
mAbs, 2009 Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing US Food and Drug Administration review, and might be ...
openaire +2 more sources
Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. [PDF]
, 2021 BACKGROUND Denosumab discontinuation without subsequent bisphosphonates (BPs) is associated with bone loss and multiple vertebral fractures. OBJECTIVE Identifying risk factors for bone loss and vertebral fractures after denosumab discontinuation.
Everts-Graber, J +5 more
core +3 more sources
Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
Frontiers in Oncology, 2020 Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of ...
Hengyuan Li +7 more
doaj +1 more source
Does denosumab exert a protective effect against COVID-19? Results of a large cohort study
Frontiers in Endocrinology, 2023 IntroductionDenosumab is a monoclonal antibody blocking the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand (RANK/RANKL) pathway, thus inhibiting osteoclastogenesis.
Sara Cassibba +6 more
doaj +1 more source
Journal of Bone Oncology, 2022 Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with multiple
Benoit Cadieux +8 more
doaj +1 more source
A review of denosumab for the treatment of osteoporosis [PDF]
, 2014 Tsuyoshi Miyazaki,1,2 Fumiaki Tokimura,1 Sakae Tanaka3 1Department of Orthopedic Surgery, 2Department of Geriatric Medicine, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Itabashi-ku, Tokyo, Japan; 3Department of Orthopedic Surgery,
Tokimura F +5 more
core +1 more source